I agree with you PSFlyer that ADXS is better suited as an investment rather than a trade. Price action with this company is irrational. Longer term however, you can't deny the potential.
Results from cervical cancer study showed good safety profile and further improvements. Survival up to 28% from 22% and this is the low dose. The higher dosing could & should make results even better in the future. Add this to the list of positive advancements made in the last few months. Price is lagging
News 
Market Data 
Discover 
AI
